RxDoctor Payments DataLook up a doctor →

Karen Roden

Nurse Practitioner · Knoxville, TNNPI 1225023781

Payments from drug & device makers

$264,937in general payments, 2019–2025

Across 861 payments — averaging $307.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$158K
  • Genentech USA, Inc.$50K
  • Sanofi$20K
  • Regeneron Healthcare Solutions, Inc.$18K
  • Amgen$12K
  • Novartis$957
  • plus $6K from 34 others

What the payments were for

  • Consulting fees$4,4682%
  • Speaking & faculty fees$204,35977%
  • Travel & lodging$33,48613%
  • Food & beverage$22,1828%
  • Education$4430%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$264,937 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$307,555
Medicare patients
257
Services billed
7,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor13$118,450
Dupixent SyringeDupilumab19$109,175
Trelegy ElliptaFluticasone/Umeclidin/Vilanter120$96,138
Breo ElliptaFluticasone/Vilanterol40$28,217
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$11,933
Advair HfaFluticasone Propion/Salmeterol23$9,920
Arnuity ElliptaFluticasone Furoate21$7,324
Azelastine Hcl164$4,884
Ipratropium Bromide102$4,710
Epinephrine11$3,268
Fluticasone Propionate236$3,222
Albuterol Sulfate HfaAlbuterol Sulfate59$2,381
Wixela InhubFluticasone Propion/Salmeterol16$2,241
Montelukast Sodium184$1,170
Esomeprazole Magnesium33$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$626$131,678181 claims
Grifols USA, LLCProlastin C$296$118,45013 claims
Hikma Pharmaceuticals USAEpinephrine$32$3,26811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →